GlassScriptPhysician profile
Christa Michelle Tomc
NPI 1184980294
$12,860.91
in general payments reported to CMS, 2019-2025
33 companies · $3,707 in 2025
The $3,707 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $528 · 2021: $1,118 · 2022: $1,106 · 2023: $3,135 · 2024: $2,639 · 2025: $3,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,310 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,310.33 |
| Education | $169.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,132.13 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Galderma Laboratories, L.P. | $1,006.94 | 2019-2025 | Aklief, Dysport, Oracea |
| Regeneron Healthcare Solutions, INC. | $942.75 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $929.59 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $906.61 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $667.14 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $640.73 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $568.18 | 2019-2025 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $466.23 | 2023-2025 | Zoryve |
| Amgen INC. | $436.56 | 2020-2025 | Otezla, Otezla |
| Almirall LLC | $398.58 | 2019-2025 | Seysara |
| Dermavant Sciences, INC. | $391.70 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $388.71 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $385.51 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $372.22 | 2020-2025 | Cabtreo, Jublia, Arazlo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $290.29 | 2019-2022 | |
| Incyte Corporation | $275.54 | 2022-2025 | Opzelura |
| Genzyme Corporation | $260.11 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $205.79 | 2019-2025 | |
| Merz North America, INC. | $196.57 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $175.00 | 2021 | |
| Revance Therapeutics, INC. | $146.68 | 2025 | Daxi, Daxxify |
| Biofrontera INC. | $130.70 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $98.70 | 2022-2025 | |
| Botanix Sb INC | $96.40 | 2025 | Sofdra |
| Medimetriks Pharmaceuticals, INC. | $94.01 | 2020-2022 | |
| Pfizer INC. | $81.77 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $49.17 | 2020-2021 | |
| Organon LLC | $48.90 | 2025 | Vtama |
| Cipher Pharmaceuticals US LLC | $29.77 | 2025 | Spinosad, Natroba |
| Lnhc, INC | $20.71 | 2025 | Zelsuvmi |
| Aclaris Therapeutics, INC. | $16.24 | 2019 | |
| Dermira, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Tomc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.